Bregal Sagemount has completed a strategic growth investment in LSPedia, a pharmaceutical industry software provider specializing in compliance and supply chain traceability solutions. The deal, announced this week, marks continued private equity interest in healthcare technology companies supporting drug manufacturers' regulatory requirements.

LSPedia, founded in 2013, operates from Farmington Hills, Michigan and serves pharmaceutical clients with software that tracks products through complex supply chains while ensuring regulatory compliance. Its solutions help manufacturers navigate FDA requirements and maintain product integrity from production to distribution.

Bregal Sagemount, the New York-based growth equity firm that launched in 2012, typically deploys $20 million to $400 million per transaction across healthcare IT, business services, and financial technology sectors. The firm usually takes lead positions in both control and non-control investments, targeting companies with strong growth prospects.

The investment reflects growing demand for pharmaceutical compliance software as regulations tighten and supply chain complexity increases. With deal terms undisclosed, this partnership positions LSPedia to expand its market reach while giving Sagemount exposure to the specialized healthcare IT segment.